In in vivo studies, GCK targets RA-associated inflammation by regulating TNF-α/TNFR2 signaling in synovial cells and significantly alleviates joint pathology in AA rats, including attenuation of synovial hyperplasia and inhibition of RA-FLS proliferation/migration (59). This evidence concerns the gene TNFRSF1B and rheumatoid arthritis.